智通财经APP获悉，海西新药(02637)午后涨超10%，高见145.9港元，再创上市新高，较招股价86.4港元累涨近70%。截至发稿，涨10.87%，报145.9港元，成交额1671.42万港元。
公开资料显示，海西新药是一家处于商业化阶段的制药公司。截至招股书披露日，海西新药获批上市的仿制药产品有15款，产品组合涵盖了多个治疗领域，包括消化系统、心血管系统、内分泌系统、神经系统等。2021年以来，安必力、瑞安妥、海慧通、赛西福、相继入选国家药品集中采购计划。从2024年的营收情况看，这四款核心仿制药贡献了海西新药超过九成的收入，达到4.25亿元。
值得注意的是，海西新药已布局创新药研发管线。其中，C019199是一种靶向CSF-1R/DDR1/VEGFR2的泛癌种免疫治疗药物，目前针对骨肉瘤、腱鞘巨细胞瘤等适应症处于I/II期临床阶段，计划于2025年下半年启动针对骨肉瘤的III期试验。而HXP056为用于治疗湿性年龄相关性黄斑变性的口服药物，预期将于2025年底完成I期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.